Figure 1.
Figure 1. Suggested strategies for outpatient management of HMB associated with anticoagulants. (*) Ensure good anticoagulant control if on warfarin therapy and compliance if receiving DOAC therapy. If started on combined hormonal contraceptive (CHC), high-dose oral progestogen, or depot medroxyprogesterone acetate (DMPA), hormonal therapy must be discontinued before cessation of anticoagulants. **The recommended dose in the United States; in Europe, the recommended dose is 1 g orally 3 times per day for up to 4 days (dose may be increased to maximum of 4 g/d). ***Thrombotic risk unknown when combined with reduced-dose DOACs. bid, twice per day; OD, once per day; POP, progestin-only pill; tid, 3 times per day.

Suggested strategies for outpatient management of HMB associated with anticoagulants. (*) Ensure good anticoagulant control if on warfarin therapy and compliance if receiving DOAC therapy. If started on combined hormonal contraceptive (CHC), high-dose oral progestogen, or depot medroxyprogesterone acetate (DMPA), hormonal therapy must be discontinued before cessation of anticoagulants. **The recommended dose in the United States; in Europe, the recommended dose is 1 g orally 3 times per day for up to 4 days (dose may be increased to maximum of 4 g/d). ***Thrombotic risk unknown when combined with reduced-dose DOACs. bid, twice per day; OD, once per day; POP, progestin-only pill; tid, 3 times per day.

Close Modal

or Create an Account

Close Modal
Close Modal